Effect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive Patients

Pasini, Anna Fratta; Garbin, Ulisse; Nava, Maria Cristina; Stranieri, Chiara; Pellegrini, Michele; Boccioletti, Veronica; Luchetta, Maria Laura; Fabrizzi, Paolo; Cascio, Vincenzo Lo; Cominacini, Luciano

doi:10.1016/j.amjhyper.2006.09.020

Cited by 67 publications

(56 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five of the 16 studies analyzed effects of different classes of antihypertensive drugs on endothelial function [8,12,16,22,23]. Three of them involving 191 patients compared the effect of angiotensin converting enzyme inhibitors (ACEI) and beta-blockers on FMD changes [7,12,23].…”

Section: Beta-blockers Vs Other Antihypertensive Drugsmentioning

confidence: 99%

Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Beta-blockers Vs Other Antihypertensive Drugsmentioning

confidence: 99%

Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, Zofenopril is associated with such pleiotropic effects as cardioprotection and prevention of endothelial dysfunction; anti-ischemic, antiinflammatory and antiatherogenic effects; its angiogenesis ability; and its ability to reverse development of apoptosis. The presence of the sulfhydryl group in Zofenopril gives it the ability to reduce oxidative stress, compound free radicals, increase production of nitric oxide, and provide an antiatherogenic and vasoprotective effect [1,2]. In accordance with that, Zofenopril increases coronary circulation and reduces ischemia, which lets us characterize Zofenopril as an antihypertensive drug with cardioprotective properties [3].…”

Section: Introductionmentioning

confidence: 74%

Antiremodelling Efficacy and Clinical Safety of Zofenopril in Patients with Grade 1and 2 Hypertension

Khamidullaeva¹,

Abdullaeva²,

Хафизова³

et al. 2015

Int J Biomed

View full text Add to dashboard Cite

Objective: to estimate the antihypertensive, antiremodelling efficacy and clinical tolerability of the monotherapy with Zofenopril in patients with Grade 1 and 2 hypertension (HT 1 and 2) Materials and Methods: The study included 30 patients aged from 30 to 60 years with HT 1 and 2 (ESH/ESC, 2013) without severe comorbidities and cardiovascular complications. Zofenopril was prescribed as monotherapy to HT patients who had never been treated before or patients after one week of lavage from previous antihypertensive therapy, who did not reach target levels of blood pressure (BP). Before and during treatment all patients were checked on office BP using Korotkov's method and ambulatory blood pressure monitoring (ABPM). Echocardiography and Doppler sonography were carried out by standard methods using the recommendations of the American Society of Echocardiography. Intima-media thickness (IMT) of the carotid artery and brachial artery was measured by a 7.5 MHz high-resolution ultrasound. Assessment of flow-mediated dilation (FMD) of the brachial artery was used as a method of determining endothelial function.Results: A 12-week monotherapy with Zofenopril in average daily dose of 36.0±9.54 mg showed a high antihypertensive efficacy and a good safety profile without side effects. We noted a reliable decrease in systolic BP (SBP), diastolic BP (DBP), mean BP, and pulse pressure by -19.53±5.93%, -18.64±7.18%, -19.05±6.14%, and -20.65±12.07%, respectively. Target SBP, DBP, and SBP+DBP were reached in 90%, 86.6%, and 83.3% of patients, respectively. We found a significant regression of LVH, significant improvement in volume indicators of LV echogeometry and parameters of FMD of the brachial artery, as well as a decrease in IMT of carotid and brachial arteries. Monotherapy with Zofenopril showed metabolic neutrality regarding the lipid and carbohydrate metabolism, a good safety profile without the side effects and undesired events.

show abstract

“…Z is a sulfhydryl ACE inhibitor highly lipophilic and with tissueprotective properties [4,[24][25][26]. Since its selective, long-acting ACE inhibitory activity, it appears beneficial and well tolerated for the treatment of a number of cardiovascular diseases (eg., acute myocardial infarction, [27][28][29] heart failure, [30,31] and essential hypertension [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Treatment of hypertension: mono-therapy versus [Zofenopril and Hydrochlorothiazide] combined therapy: A review

Crespi¹

2017

Clin Res Trials

View full text Add to dashboard Cite

The need of at least two antihypertensive drugs to achieve optimal blood pressure (BP) control in patients with hypertension appears more and more evident. In particular, the combination of the angiotensin-converting enzyme inhibitor zofenopril together with hydrochlorothiazide (diuretic) at the dose 30/12.5 mg/day respectively is now approved in Italy, France, Switzerland and Greece for the treatment of mild to moderate hypertension.The aim of this work is therefore to collect results from all available reports in order to analyse efficacy, safety and metabolic effects of such combined therapy versus Zofenopril alone. Efficacy and safety data were threfore assessed taking into account the number of subjects (weighted analysis).It emerges that in various clinical trials the combined therapy was significantly more effective in treating hypertension when comparing to mono-therapy with the further advantage of a safety profile. Therefore the combined therapy analysed here appears to be a positive improvement of the currently available therapy for patients with BP.

show abstract

Effect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive Patients

Abstract: Our results suggest that in mildly hypertensive patients without organ damage zofenopril, beyond its BP-lowering effects and through its sustained antioxidant activity, offers important advantages in reducing endothelial activation.

Cited by 67 publications

References 28 publications

Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials

Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials

Antiremodelling Efficacy and Clinical Safety of Zofenopril in Patients with Grade 1and 2 Hypertension

Treatment of hypertension: mono-therapy versus [Zofenopril and Hydrochlorothiazide] combined therapy: A review

Contact Info

Product

Resources

About